Enzo Biochem (ENZ) 10-Q 11 Jun 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Apr. 30, 2021	Jun. 07, 2021
Document Information Line Items
Entity Registrant Name	ENZO BIOCHEM INC
Document Type	10-Q
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding		48,471,771
Amendment Flag	false
Entity Central Index Key	0000316253
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Apr. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	001-09974
Entity Incorporation, State or Country Code	NY
Entity Interactive Data Current	Yes

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
ASSETS
Cash and cash equivalents	$ 15,089	$ 47,865
Marketable securities	29,932
Accounts receivable, net	11,475	9,141
Inventories	11,007	7,784
Prepaid expenses	3,838	3,975
Total current assets	71,341	68,765
Property, plant, and equipment, net	15,625	14,482
Right-of-use assets	17,411	19,916
Goodwill	7,452	7,452
Intangible assets, net	315	538
Other, including restricted cash of $750	1,479	1,385
Total assets	113,623	112,538
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable - trade	6,014	8,503
Accrued liabilities	12,528	12,833
Current portion of operating lease liabilities	3,442	4,121
Other current liabilities and finance leases short term	230	344
Other short term debt	7,000	7,000
Total current liabilities	29,214	32,801
Other liabilities and finance leases long term	136	192
Operating lease liabilities, non-current	14,916	16,679
Long term debt - net	4,390	4,485
Total liabilities	48,656	54,157
Commitments and contingencies – see Note 12
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 48,471,771 at April 30, 2021 and 47,895,050 at July 31, 2020	485	479
Additional paid-in capital	336,859	334,473
Accumulated deficit	(273,645)	(278,252)
Accumulated other comprehensive income	1,268	1,681
Total stockholders’ equity	64,967	58,381
Total liabilities and stockholders’ equity	$ 113,623	$ 112,538

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
Statement of Financial Position [Abstract]
Other, including restricted cash (in Dollars)	$ 750	$ 750
Preferred stock par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	48,471,771	47,895,050
Common stock, shares outstanding	48,471,771	47,895,050

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Income Statement [Abstract]
Revenues	$ 32,797	$ 16,903	$ 92,918	$ 56,494
Operating costs and expenses:
Cost of revenues	16,751	12,478	49,154	40,574
Research and development	836	1,163	2,388	3,282
Selling, general and administrative	12,082	11,061	33,109	32,893
Legal and related expense	1,061	1,925	3,993	5,681
Total operating costs and expenses	30,730	26,627	88,644	82,430
Operating income (loss)	2,067	(9,724)	4,274	(25,936)
Other income (expense):
Interest, net	60	87	(40)	495
Other	(88)	135	(55)	334
Foreign exchange (loss) gain	(33)	(358)	428	(88)
Total other income (expense)	(61)	(136)	333	741
Income (loss) before income taxes	2,006	(9,860)	4,607	(25,195)
Income taxes
Net income (loss)	$ 2,006	$ (9,860)	$ 4,607	$ (25,195)
Net income (loss) per common share:
Basic (in Dollars per share)	$ 0.04	$ (0.21)	$ 0.10	$ (0.53)
Diluted (in Dollars per share)	$ 0.04	$ (0.21)	$ 0.10	$ (0.53)
Weighted average common shares outstanding:
Basic (in Shares)	48,391	47,780	48,097	47,668
Diluted (in Shares)	48,788	47,780	48,201	47,668

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 2,006	$ (9,890)	$ 4,607	$ (25,195)
Other comprehensive loss:
Foreign currency translation adjustments	(2)	284	(413)	(70)
Comprehensive income (loss)	$ 2,004	$ (9,576)	$ 4,194	$ (25,265)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Balance at Jul. 31, 2019	$ 476	$ 332,704	$ (249,732)	$ 2,580	$ 86,028
Balance (in Shares) at Jul. 31, 2019	47,556,807
Net income (loss)			(25,195)		(25,195)
Share-based compensation charges		728			728
Vesting of restricted stock
Vesting of restricted stock (in Shares)	811
Issuance of common stock for employee 401(k) plan match	$ 3	836			839
Issuance of common stock for employee 401(k) plan match (in Shares)	333,265
Foreign currency translation adjustments				(70)	(70)
Balance at Apr. 30, 2020	$ 479	334,268	(274,927)	2,510	62,330
Balance (in Shares) at Apr. 30, 2020	47,890,883
Balance at Jan. 31, 2020	$ 476	333,225	(265,067)	2,226	70,860
Balance (in Shares) at Jan. 31, 2020	47,557,618
Net income (loss)			(9,860)		(9,890)
Share-based compensation charges		209			209
Issuance of common stock for employee 401(k) plan match	$ 3	834			837
Issuance of common stock for employee 401(k) plan match (in Shares)	333,265
Foreign currency translation adjustments				284	284
Balance at Apr. 30, 2020	$ 479	334,268	(274,927)	2,510	62,330
Balance (in Shares) at Apr. 30, 2020	47,890,883
Balance at Jul. 31, 2020	$ 479	334,473	(278,252)	1,681	58,381
Balance (in Shares) at Jul. 31, 2020	47,895,050
Net income (loss)			4,607		4,607
Share-based compensation charges		640			640
Exercise of stock options	$ 1	96			97
Exercise of stock options (in Shares)	34,667
Vesting of restricted stock
Vesting of restricted stock (in Shares)	817
Issuance of common stock for bonus payments	$ 3	872			875
Issuance of common stock for bonus payments (in Shares)	332,700
Issuance of common stock for employee 401(k) plan match	$ 2	778			780
Issuance of common stock for employee 401(k) plan match (in Shares)	208,537
Foreign currency translation adjustments				(413)	(413)
Balance at Apr. 30, 2021	$ 485	336,859	(273,645)	1,268	64,967
Balance (in Shares) at Apr. 30, 2021	48,471,771
Balance at Jan. 31, 2021	$ 482	335,688	(275,651)	1,270	61,789
Balance (in Shares) at Jan. 31, 2021	48,227,750
Net income (loss)			2,006		2,006
Share-based compensation charges		297			297
Exercise of stock options	$ 1	96			97
Exercise of stock options (in Shares)	34,667
Vesting of restricted stock
Vesting of restricted stock (in Shares)	817
Issuance of common stock for employee 401(k) plan match	$ 2	778			780
Issuance of common stock for employee 401(k) plan match (in Shares)	208,537
Foreign currency translation adjustments				(2)	(2)
Balance at Apr. 30, 2021	$ 485	$ 336,859	$ (273,645)	$ 1,268	$ 64,967
Balance (in Shares) at Apr. 30, 2021	48,471,771

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Statement of Cash Flows [Abstract]
Net income (loss)	$ 4,607	$ (25,195)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of property, plant and equipment	1,724	1,700
Amortization of intangible assets	244	451
Share-based compensation charges	640	728
Accrual for share-based 401(k) employer match expense	559	631
Unrealized loss on marketable securities	91
Foreign exchange (gain)/loss	(494)	8
Changes in operating assets and liabilities:
Accounts receivable	(2,292)	3,942
Inventories	(3,159)	(147)
Prepaid expenses and other assets	29	223
Accounts payable – trade	(2,473)	1,211
Accrued liabilities, other current liabilities and other liabilities	803	4,330
Total adjustments	(4,328)	13,077
Net cash provided by (used in) operating activities	279	(12,118)
Cash flows from investing activities:
Capital expenditures	(2,870)	(719)
Purchases of marketable securities	(30,023)
Net cash used in investing activities	(32,893)	(719)
Cash flows from financing activities:
Proceeds from borrowings under government programs and mortgage agreement		7,412
Proceeds from exercise of stock options	97
Repayments under mortgage agreement and finance leases	(283)	(321)
Net cash (used in) provided by financing activities	(186)	7,091
Effect of exchange rate changes on cash and cash equivalents	24	7
Decrease in cash and cash equivalents and restricted cash	(32,776)	(5,739)
Cash and cash equivalents and restricted cash - beginning of period	48,615	60,896
Total cash and cash equivalents and restricted cash - end of period	15,839	55,157
The composition of total cash and cash equivalents and restricted cash is as follows:
Cash and cash equivalents	15,089	54,407
Restricted cash included in other assets	750	750
Total cash and cash equivalents and restricted cash	$ 15,839	$ 55,157

Basis of Presentation

Basis of Presentation	9 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics, Enzo Realty LLC and Enzo Realty II LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The Company has three reportable segments: Clinical Services, Products, and Therapeutics. The consolidated balance sheet as of April 30, 2021, the consolidated statements of operations, comprehensive income (loss) and stockholders’ equity for the three and nine months ended April 30, 2021, and the consolidated statements of cash flows for the nine months ended April 30, 2021 (the “interim statements”) are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The interim statements should be read in conjunction with the consolidated financial statements for the fiscal year ended July 31, 2020 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2020 has been derived from the audited financial statements at that date. The results of operations for the nine months ended April 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2021. While the rate of transmission of COVID-19 is declining in the US and Europe, it continues to spread in other parts of the world and negatively impact the world economy. Federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, a significant reduction in physician office visits, the cancellation of elective medical procedures, customers of our products remaining closed or continuing to severely curtail their operations (voluntarily or in response to government orders), and the continuation of work-from-home or shelter-in-place policies. The COVID-19 impact on the Company’s operations is consistent with the overall industry and publicly issued statements from competitors, partners, and vendors. The extent to which our businesses may continue to be affected by the COVID-19 pandemic will largely depend on both current and future developments, including its duration, the emergence and spread of variants, its treatment with authorized vaccines and vaccines in various stages of development and federal approval, work and travel advisories and restrictions, and the timing of their easing, all of which are highly uncertain and cannot be reasonably predicted at this time. Global supply chain issues due to the pandemic continue to hamper both the manufacturing of products within the life science division as well as testing capabilities in the clinical laboratory. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. COVID 19 The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions including, but not limited to, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of April 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s patient self-pay revenue concessions and credit losses in the Clinical Services segment, accounts receivable, inventories and the carrying value of goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods. We fully expect COVID-19 volume to decline in the quarters ahead as the percentage of Americans who are vaccinated increases. Effect of New Accounting Pronouncements Pronouncements Issued but Not Yet Adopted In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326) In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations. Concentration Risk Other than the Medicare program, two providers whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represent approximately 36% and 35% of Clinical Services net revenue for the three and nine month periods ended April 30, 2021. Other than the Medicare program, one provider whose programs are included in those categories represents approximately 21% of Clinical Services net revenue for both the three and nine month periods ended April 30, 2020. As of April 30, 2021, the Medicare program represents 15%, a provider in the third party category represents 13%, and a government payer in the patient self-pay category represents 10% of Clinical Services net receivables. Income Taxes The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. It is the Company’s policy to provide for uncertain tax positions, if any, and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. Due to our tax net operating loss carryforwards, we do not provide for an income tax provision on pre-tax income in the fiscal 2021 periods. We maintain a full valuation allowance on all tax assets and, as a consequence, do not provide any tax benefit for the fiscal 2020 period losses. Fair Value Measurements The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest. Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level 3 Valuations derived from valuation techniques in which one or more significant inputs are unobservable. Marketable securities The Company limits its credit risk associated with investments by investing in a mutual fund and an exchange traded fund (ETF) which hold highly rated corporate bonds, asset backed securities, municipal bonds, mortgage obligations and government obligations. These investments are classified as trading securities and are Level 1 fair value investments. As of April 30, 2021, the fair value of these investments was $29,932 and the cost basis was $30,023. We recognized unrealized losses of $91 for the three and nine months ended April 30, 2021.

Net income (loss) per share

Net income (loss) per share	9 Months Ended
	Apr. 30, 2021
Earnings Per Share [Abstract]
Net income (loss) per share	Note 2 – Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. For the three and nine months ended April 30, 2021, approximately 397,000 and 104,000 weighted average stock options and performance stock units respectively were included in the calculation of diluted weighted average shares outstanding. As a result of the net loss for the three and nine month periods ended April 30, 2020, diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and performance stock units because to do so would be antidilutive. For the three and nine months ended April 30, 2020, approximately 40,000 and 56,000 respectively, of potential common shares (“in the money options”) were excluded from the calculation of diluted earnings per share. For the three and nine months ended April 30, 2021, the effect of approximately 814,000 and 1,686,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive. For the three and nine months ended April 30, 2020, the effect of approximately 2,201,000 and 1,805,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Apr. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 3 – Revenue Recognition Clinical Services Revenue Service revenues in the Company’s clinical services business accounted for approximately 76% of the Company’s total revenues for the three and nine months ended April 30, 2021 and 58% of the Company’s total revenues for the three and nine months ended April 30, 2020, and are primarily comprised of a high volume of relatively low-dollar transactions. The services business, which provides clinical testing services, satisfies its performance obligation and recognizes revenues upon completion of the testing process for a specific patient and reporting to the ordering physician. The Company may also perform clinical testing services for other laboratories and will recognize revenue from those services when reported to the ordering laboratory. The Company estimates the amount of consideration it expects to receive from customer groups using the portfolio approach. These estimates of the expected consideration include the impact of contractual allowances and price concessions on our customer group portfolios consisting of healthcare insurers, government payers, client payers and patients as described below. Contracts with customers in our laboratory services business do not contain a financing component, based on the typically limited period of time between performance of services and collection of consideration. The transaction price includes variable consideration in the form of the contractual allowance and price concessions as well as the collectability of the transaction based on patient intent and ability to pay. The Company uses the expected value method in estimating the amount of the variability included in the transaction price. The following are descriptions of our laboratory services business portfolios: Third party payers and Health Maintenance Organizations (HMO’s) Reimbursements from third party payers, primarily healthcare insurers and HMO’s are based on negotiated fee-for-service schedules and on capitated payment rates. Revenues consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical collection and denial experience and the terms of the Company’s contractual arrangements. Adjustments to the allowances, based on actual receipts from the third-party payers, are recorded upon settlement. Collection of the consideration the Company expects to receive is normally a function of providing complete and correct billing information to these third party payers within the various filing deadlines, and typically occurs within 30 to 90 days of billing. Provided the Company has billed healthcare insurers accurately with complete information prior to the established filing deadline, there has historically been little to no collection risk. If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and if so, will reserve accordingly for the billing. Third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. Our revenues may be subject to adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payers in interpretations, requirements, and “conditions of participation” in various programs. Government Payer - Medicare Reimbursements from Medicare are based on fee-for-service schedules set by Medicare, which is funded by the government. Revenues consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from Medicare, which considers historical collection and denial experience and other factors. Adjustments to the allowances, based on actual receipts from the government payers, are recorded upon settlement. Collection of consideration the Company expects to receive is normally a function of providing the complete and correct billing information within the various filing deadlines and typically occurs within 60 days of billing. Provided the Company has billed the government payer accurately with complete information prior to the established filing deadline, there has historically been little to no collection risk. If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and, if so, it will reserve accordingly for the billing. Patient self-pay Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Coinsurance and deductible responsibilities based on fees negotiated with healthcare insurers are also billed to insured patients and included in this portfolio. Collection of billings from patients is subject to credit risk and ability of the patients to pay. Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with the Company’s policies and implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive from patients, which considers historical collection experience and other factors including current market conditions. Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement. Patient responsibility is invoiced and if it reaches 91 days outstanding, the account is sent to a collection agency for further processing. After the account has been with the collection agency for at least 105 days, and is determined to be uncollectable it is written off. The following table represents clinical services net revenues and percentages by type of customer: Three months ended Three months ended Revenue category Third-party payer $ 16,135 64 % $ 5,082 52 % Medicare 2,952 12 1,870 19 Patient self-pay 2,468 10 1,655 17 HMO’s 3,463 14 1,132 12 Total $ 25,018 100 % $ 9,739 100 % Nine months ended Nine months ended Revenue category Third-party payer $ 44,138 63 % $ 17,878 51 % Medicare 10,265 15 8,048 23 Patient self-pay 6,524 9 4,621 13 HMO’s 9,302 13 4,485 13 Total $ 70,229 100 % $ 35,032 100 % For nine months ended April 30, 2021 and 2020, all of the Company’s clinical services revenues were generated within the United States. Products Revenue Products revenues consist of the sale of single-use products used in the identification of genomic information and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Payment terms for shipments to end-user and distributor customers may range from 30 to 90 days. Any claims for credit or return of goods may be made generally within 30 days of receipt. Revenues are reduced to reflect estimated credits and returns, although historically these adjustments have not been material. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. Products revenue by geography is as follows: Three Months Ended Nine Months Ended 2021 2020 2021 2020 United States $ 3,941 $ 3,520 $ 11,410 $ 11,854 Europe 2,732 1,802 7,798 5,777 Asia Pacific 1,106 1,095 3,481 3,084 Products revenue $ 7,779 $ 6,417 $ 22,689 $ 20,715

Supplemental Disclosure for Sta

Supplemental Disclosure for Statement of Cash Flows	9 Months Ended
	Apr. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Supplemental disclosure for statement of cash flows	Note 4 – Supplemental disclosure for statement of cash flows In the nine months ended April 30, 2021 and 2020, interest paid by the Company was $177 and $204, respectively. For the nine months ended April 30, 2021 and 2020, the net reductions in the measurement of right of use assets and liabilities included in cash flows from operating activities was $67 and $127, respectively. The changes are included in changes in accrued liabilities, other current liabilities, and other liabilities in the statement of cash flows. In January 2021, the Company issued 332,700 shares of common stock to two senior executives in settlement of their accrued bonuses totaling $875. During the nine months ended April 30, 2021 and 2020, the Company issued 208,537 and 333,265 shares of common stock in connection with its share based 401(k) employer match in the amount of $780 and $836, respectively.

Inventories

Inventories	9 Months Ended
	Apr. 30, 2021
Inventory Disclosure [Abstract]
Inventories	Note 5 – Inventories Inventories consist of the following at April 30: April 30, July 31, Raw materials $ 1,287 $ 1,019 Work in process 2,489 2,587 Finished products 7,231 4,178 $ 11,007 $ 7,784

Goodwill and intangible assets

Goodwill and intangible assets	9 Months Ended
	Apr. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	Note 6 – Goodwill and intangible assets Goodwill The Company’s net carrying amount of goodwill is in the Clinical Laboratory Services segment and is $7,452 as of April 30, 2021 and 2020. Intangible assets The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences Products segment is as follows: Gross Accumulated Amortization Net July 31, 2020 $ 27,686 $ (27,148 ) $ 538 Amortization expense — (244 ) (244 ) Foreign currency translation 88 (67 ) 21 April 30, 2021 $ 27,774 $ (27,459 ) $ 315 Intangible assets, all finite-lived, consist of the following: April 30, 2021 July 31, 2020 Gross Accumulated Net Gross Accumulated Net Patents $ 11,027 $ (11,027 ) $ — $ 11,027 (11,014 ) $ 13 Customer relationships 12,058 (11,743 ) 315 12,003 (11,478 ) 525 Website and acquired content 1,025 (1,025 ) — 1,022 (1,022 ) — Licensed technology and other 494 (494 ) — 483 (483 ) — Trademarks 3,170 (3,170 ) — 3,151 (3,151 ) — Total $ 27,774 $ (27,459 ) $ 315 $ 27,686 (27,148 ) $ 538 At April 30, 2021, information with respect to acquired intangibles is as follows: Useful life assigned Weighted average Customer relationships 8 -15 years 1 year At April 30, 2021, the weighted average remaining useful life of all intangible assets was approximately one year.

Long term debt

Long term debt	9 Months Ended
	Apr. 30, 2021
Debt Disclosure [Abstract]
Long term debt	Note 7 – Long term debt In connection with the purchase of our new facility in November 2018, a wholly-owned subsidiary (the “mortgagor subsidiary”) of the Company entered into a Fee Mortgage and Security Agreement (the “mortgage agreement”) with Citibank, N.A. (the “mortgagee”). The mortgage agreement provides for a loan of $4,500 for a term of 10 years, bears a fixed interest rate of 5.09% per annum and requires monthly mortgage payments of principal and interest of $30. Debt issuance costs of $72 are being amortized over the life of the mortgage agreement. The balance of unamortized debt issuance cost was $55 at April 30, 2021. At April 30, 2021, the balance owed by the subsidiary under the mortgage agreement was approximately $4.2 million. The Company’s obligations under the mortgage agreement are secured by the new facility and by a $750 cash collateral deposit with the mortgagee as additional security. This restricted cash is included in other assets as of April 30, 2021. We assumed from the seller an operating lease for a tenant at the facility which expired on June 30, 2020. Rental income from the assumed lease for the three and nine months ended April 30, 2020 is included in Other income. The mortgage agreement includes affirmative and negative covenants and events of default, as defined. Events of default include non-payment of principal and interest on debt outstanding, non-performance of covenants, material changes in business, breach of representations, bankruptcy or insolvency, and changes in control. The mortgage includes certain financial and liquidity covenants. As of April 30, 2021, the Company was in compliance with those covenants. The liquidity covenant requires that we own and maintain at all times and throughout the remaining term of the loan at least $25 million of liquid assets, defined as time deposits, money market accounts, commercial paper and obligations issued by the U.S. government or any of its agencies. In April 2020, our subsidiary in Switzerland received a loan of CHF 0.4 million ($0.4 million, based on the foreign exchange rate as of April 30, 2021) from the Swiss government under the “Corona Krise” emergency loan program in response to the pandemic. This loan is uncollateralized, bears 0% interest, is due in 5 years, and may be repaid at any time. This loan is included in long term debt – net as of April 30, 2021. The CARES Act expanded the U.S. Small Business Administration’s (SBA) business loan program to create the Paycheck Protection Program (PPP), which provides employers with uncollateralized loans whose primary purpose is to retain or maintain workforce and salaries for a twenty four week period (“covered period”) following receipt of the loan. Currently, PPP loans have a 1% fixed interest rate and are due from two to five years. The primary features of the PPP loan program are to provide funding to companies to cover eligible expenses, and the potential for forgiveness of that portion of the loan spent on payroll and other permitted operating expenses during the covered period, subject to reductions if the borrower fails to maintain or restore employee and salary levels. We applied for the PPP loan based on the eligibility and need requirements established when the program was announced and in April 2020 received $7,000 through Citibank N.A., the Company’s existing lender, pursuant to the PPP. The PPP Loan matures on April 17, 2022 (the “Maturity Date”), accrues interest at 1% per annum and may be prepaid in whole or in part without penalty. No interest payments are due within the initial six months of the PPP Loan. Interest accrued during the initial six-month period is due and payable, together with the principal, on the Maturity Date. The Company used all proceeds from the PPP Loan to retain employees, maintain payroll and make lease and utility payments to support business continuity throughout the COVID-19 pandemic. All or a portion of the PPP Loan, including interest, could be forgiven by the SBA by applying for forgiveness and providing acceptable documentation that demonstrates the funds were used as required by the terms of forgiveness and in accordance with the SBA’s requirements. Due to complexities with respect to loan forgiveness calculations and government pronouncements with respect to expenditure eligibility, we did not recognize any loan forgiveness as of April 30, 2021 and have classified the loan as other short term debt as the loan matures in less than one year. We expect to earn loan forgiveness on all of the loan proceeds and have accrued no interest. The SBA intends to audit loans in excess of $2.0 million. The SBA also required businesses that received loans in excess of $2 million to complete a loan necessity questionnaire to evaluate the good faith certification made on their PPP applications that economic uncertainty made their loan request necessary to support ongoing operations. In April 2021 we submitted our PPP loan forgiveness application and the loan necessity questionnaire to the SBA through Citibank N.A., our intermediary lending bank. According to the SBA, its review may take up to 90 calendar days from the receipt of the loan forgiveness application and loan necessity questionnaire. No assurance can be given that we will obtain forgiveness of the PPP loan in whole or in part by July 31, 2021. Minimum future annual principal payments under these agreements as of April 30, 2021 are as follows: July 31, Total 2021 $ 7,037 2022 152 2023 160 2024 167 2025 603 Thereafter 3,476 Total principal payments 11,595 Less: current portion, included in other current liabilities and other short term debt (7,150 ) Unamortized mortgage cost (55 ) Long term debt - net $ 4,390

Leases

Leases	9 Months Ended
	Apr. 30, 2021
Leases Disclosure [Abstract]
Leases	Note 8 - Leases The Company follows ASU No. 2016-02 “Leases (Topic 842)”, which requires leases with durations greater than twelve months to be recognized on the balance sheet. The Company determines if an arrangement is or contains a lease at contract inception. The Company leases buildings, office space, patient service centers, and equipment primarily through operating leases, and equipment through a limited number of finance leases. Generally, a right-of-use asset, representing the right to use the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company primarily uses its incremental borrowing rate in determining the present value of lease payments as the Company’s leases generally do not provide an implicit rate. The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (i.e. payments related to maintenance fees, utilities, etc.), which have generally been combined and accounted for as a single lease component. The Company’s leases have remaining terms of less than 1 year to 8 years, some of which include options to extend the leases for up to 5 years. The Company’s lease terms may include renewal options that are reasonably certain to be exercised and termination options that are reasonably certain not to be exercised. Certain of the Company’s lease agreements include rental payments adjusted periodically for inflation or a market rate which are included in the lease liabilities. Leases Balance Sheet Classification April 30, 2021 Assets Operating Right-of-use assets $ 17,411 Finance Property, plant and equipment, net (a) 267 Total lease assets $ 17,678 Liabilities Current: Operating Current portion of operating lease liabilities $ 3,442 Finance Finance leases short term 72 Non-current: Operating Operating lease liabilities, non-current 14,916 Finance Other liabilities and finance leases long term 136 Total lease liabilities $ 18,566 (a) Accumulated amortization of finance lease assets was approximately $1.1 million as of April 30, 2021. Components of lease cost were as follows: Three months ended Nine months ended 2021 2020 2021 2020 Operating lease cost $ 1,271 $ 1,466 $ 4,265 $ 4,414 Finance lease cost: Amortization of leased assets 19 61 118 177 Interest on lease liabilities 3 7 12 29 Total lease cost $ 1,293 $ 1,534 $ 4,395 $ 4,620 The maturity of the Company’s lease liabilities as of April 30, 2021 is as follows: Maturity of lease liabilities, years ending July 31, Operating leases Finance leases Total 2021 $ 1,181 $ 22 $ 1,203 2022 4,017 88 4,105 2023 3,318 88 3,406 2024 3,173 31 3,204 2025 3,145 — 3,145 Thereafter 6,370 — 6,370 Total lease payments 21,204 229 21,433 Less: Interest (a) (2,846 ) (18 ) (2,864 ) Present value of lease liabilities $ 18,358 $ 211 $ 18,569 (a) Primarily calculated using the Company’s incremental borrowing rate. Lease term and discount rate for the nine months ended April 30, 2021 were as follows: Lease term and discount rate Weighted-average remaining lease term (years): Operating leases 5.8 years Finance leases 2.7 years Weighted-average discount rate: Operating leases 4.97 % Finance leases 8.25 % See Note 4 for cash flow information on cash paid for amounts included in the measurement of lease liabilities for the nine months ended April 30, 2021.

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Apr. 30, 2021
Payables and Accruals [Abstract]
Accrued Liabilities	Note 9 – Accrued Liabilities At April 30, accrued liabilities consist of: April 30, July 31, Payroll, benefits, and commissions $ 4,273 $ 5,227 Professional fees 627 710 Legal 2,909 2,647 Deferred revenue – CARES Act Advance Payment 2,414 2,526 Other 2,305 1,723 $ 12,528 $ 12,833 Deferred revenue In order to increase cash flow to providers of services and suppliers impacted by the pandemic, the Centers for Medicare and Medicaid Services (CMS) expanded its Accelerated and Advance Payment Program to a broader group of Medicare providers. We applied for and received a $2,526 payment advance from this program in April 2020. The recoupment by CMS of our advance payment had been scheduled to begin 120 days after the date of receipt, at which time every claim we submit from that point would be automatically offset to repay the advance payment. In October 2020, the Continuing Appropriations Act, 2021 and Other Extensions Act amended the repayment terms of the Advance Payment Program. The recoupment period was extended and the automatic recoupment begins one year after the date the advance payment was received. CMS began recoupment of our advance in April 2021. During the next 11 months, the recoupment rate will be 25% of claims processed and repayment occurs through an automatic recoupment of our Medicare payments. If the total amount of the advance payment is not recovered within 29 months from the date the advance was received, a demand letter for the outstanding balance will be issued. We expect the entire balance of the payment advance to be recouped by the end of the 11 month period and include the remaining balance in accrued liabilities at April 30, 2021. Self-Insured Medical Plan The Company self-funds medical insurance coverage for certain of its U.S. based employees. The risk to the Company is believed to be limited through the use of individual and aggregate stop loss insurance. As of April 30, 2021, the Company has established a reserve of $243, which is included in accrued liabilities, for claims that have been reported but not paid and for claims that have been incurred but not reported. The reserve is based upon the Company’s historical payment trends, claim history and current estimates.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Apr. 30, 2021
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	Note 10 – Stockholders’ Equity Controlled Equity Offering The Company has a Controlled Equity Offering SM In September 2017, the Company filed with the SEC a Form S-3 “shelf” registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued and sold under the existing Sales Agreement in an aggregate amount of up to $19.2 million. A total of $150 million of securities may be sold under this shelf registration, which was declared effective September 2017. The Form S-3 expired in October 2020 but may be refiled at any time at the discretion of the Company. During the nine months ended April 30, 2021 and 2020, the Company did not sell any shares of Common Stock under the Sales Agreement. Share-based compensation In January 2011, the Company’s stockholders approved the adoption of the 2011 Incentive Plan (the “2011 Plan”) for the issuance of equity awards, including, among others, options, restricted stock, restricted stock units and performance stock units for up to 3,000,000 shares of common stock. On January 5, 2018, the Company’s stockholders approved the amendment and restatement of the 2011 Plan (the “Amended and Restated 2011 Plan”) to increase the number of shares of common stock available for grant under the 2011 Plan by 2,000,000 shares of common stock bringing the total number of shares available for grant to 5,000,000 shares of common stock. On October 7, 2020, the Company’s Board of Directors approved the amendment and restatement of the Amended and Restated 2011 Plan, with an effective date of October 7, 2020 and subject to approval by the Company’s stockholders at the 2020 annual meeting of stockholders of the Company. The amendment and restatement of the Amended and Restated 2011 Plan was for purposes of, among other things, (i) increasing the shares of common stock available for grant under the Amended and Restated 2011 Plan by an additional 4,000,000 shares of common stock bringing the total number of shares available for grant to 9,000,000 shares of common stock and (ii) extending the term of the Amended and Restated 2011 Plan until October 7, 2030. In January 2021, the Company’s stockholders approved the amendment and restatement of the Amended and Restated 2011 Plan. The exercise price of options granted under the Amended and Restated 2011 Plan, as amended and restated, is equal to or greater than fair market value of the common stock on the date of grant. The Amended and Restated 2011 Plan, as amended and restated, will terminate at the earliest of (a) such time as no shares of common stock remain available for issuance under the plan, (b) termination of the plan by the Company’s Board of Directors, or (c) October 7, 2030. Awards outstanding upon expiration of the Amended and Restated 2011 Plan, as amended and restated, will remain in effect until they have been exercised or terminated, or have expired. As of April 30, 2021, there were approximately 4,834,000 shares of common stock available for grant under the Amended and Restated 2011 Plan, as amended and restated. The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Nine months ended 2021 2020 2021 2020 Stock options and performance stock units $ 297 $ 206 $ 638 $ 724 Restricted stock — 1 2 4 $ 297 $ 207 $ 640 $ 728 The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Nine months ended 2021 2020 2021 2020 Selling, general and administrative $ 258 $ 207 $ 574 $ 728 Cost of revenues 39 — 66 — $ 297 $ 207 $ 640 $ 728 No excess tax benefits were recognized during the nine month periods ended April 30, 2021 and 2020. Stock Option Plans The following table summarizes stock option activity during the nine month period ended April 30, 2021: Options Weighted Weighted Aggregate Outstanding at July 31, 2020 2,636,496 $ 4.05 Awarded 543,104 $ 2.57 Exercised (34,667 ) 2.80 $ Expired or forfeited (619,371 ) $ 3.40 Outstanding at end of period 2,525,562 $ 3.76 2.6 years $ 957 Exercisable at end of period 1,581,326 $ 1.6 years $ As of April 30, 2021, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $916 and the weighted average period over which the remaining expense of these awards is expected to be recognized is approximately sixteen months. The intrinsic value of in the money stock option awards at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options. Performance Stock Units To better align the long-term interest of executives with growing U.S. practices, beginning in fiscal 2018, the Company’s board of directors approved long-term incentive awards in the form of performance-based stock units (“Performance Stock Units” or “PSUs”) in addition to time based stock options. The PSUs earned will be determined over a three fiscal year performance period. The primary performance metrics will be revenue and Adjusted EBITDA growth. Payouts based on revenue and adjusted EBITDA goals will be modified based on Total Shareholder Return (“TSR”) performance relative to Enzo’s peer group. During the fiscal years ended 2020, 2019 and 2018, the Company’s board of directors approved the award of PSUs to its executive officers, whose established grant dates are in the table below. These awards provide for the grant of shares of our common stock at the end of a three–year period based on the achievement of average revenue growth and adjusted EBITDA growth over that period. During the nine months ended April 30, 2021, one former executive forfeited a total of 6,000 PSUs. During the nine months ended April 30, 2020, one former executive forfeited a total of 14,500 PSUs. During both the three and nine months ended April 30, 2021 and 2020, the Company recorded $162 and $0, respectively as compensation expense for the outstanding PSU’s. There were no PSU awards approved by the Company’s board of directors through the nine months ended April 30, 2021. The following table summarizes PSU’s granted and outstanding as of April 30, 2021: Grant Date Total Grant Forfeitures Outstanding Fair Market Value At Grant Date (000s) 10/15/2018 32,000 (6,000 ) 26,000 $ 107 10/15/2019 80,500 (14,500 ) 66,000 $ 222 10/19/2020 98,600 — 98,600 $ 207

Segment reporting

Segment reporting	9 Months Ended
	Apr. 30, 2021
Segment Reporting [Abstract]
Segment reporting	Note 11 – Segment reporting The Company has three reportable segments: Products, Clinical Services and Therapeutics. The Company’s Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Company’s Therapeutics segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. All intersegment activities are eliminated. Legal and related expenses incurred to defend the Company’s intellectual property, which may result in settlements recognized in another segment and other general corporate matters are considered a component of the Other segment. Legal and related expenses specific to other segments’ activities are allocated to those segments. Legal settlements, net, represent activities for which royalties would have been received in the Company’s Products segment. Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The following financial information represents the operating results of the reportable segments of the Company: Three months ended April 30, 2021 Clinical Services Products Therapeutics Other Consolidated Revenues – Services and Products $ 25,018 $ 7,779 — — $ 32,797 Operating costs and expenses Cost of revenues 12,733 4,018 — — 16,751 Research and development 173 643 $ 20 — 836 Selling, general and administrative 7,029 2,810 17 $ 2,226 12,082 Legal and related expenses 95 10 — 956 1,061 Total operating costs and expenses 20,030 7,481 37 3,182 30,730 Operating income (loss) 4,988 298 (37 ) (3,182 ) 2,067 Other income (expense) Interest (4 ) 11 — 53 60 Other 1 2 — (91 ) (88 ) Foreign exchange gain — (33 ) — — (33 ) Net income (loss) $ 4,985 $ 278 $ (37 ) $ (3,220 ) $ 2,006 Depreciation and amortization included above $ 399 $ 208 $ — $ 66 $ 673 Share-based compensation included in above Selling, general and administrative 9 41 — 208 258 Cost of revenues 39 — — — 39 Total $ 48 $ 41 $ — $ 208 $ 297 Capital expenditures $ 1,544 $ 180 $ — $ 23 $ 1,747 Three months ended April 30, 2020 Clinical Services Products Therapeutics Other Consolidated Revenues $ 9,739 $ 6,417 — — $ 16,156 Grant income 747 — — — 747 Total 10,486 6,417 — — 16,903 Operating costs and expenses Cost of revenues 9,133 3,345 — — 12,478 Research and development 395 580 188 — 1,163 Selling, general and administrative 5,902 2,667 — 2,492 11,061 Legal fee expense 52 — — 1,873 1,925 Total operating costs and expenses 15,482 6,592 188 4,365 26,627 Operating loss (4,996 ) (175 ) (188 ) (4,365 ) (9,724 ) Other income (expense) Interest (7 ) 11 — 83 87 Other 1 4 — 130 135 Foreign exchange loss — (358 ) — — (358 ) Net loss $ (5,002 ) (518 ) (188 ) (4,152 ) (9,860 ) Depreciation and amortization included above $ 373 278 — 66 717 Share-based compensation included in above Selling, general and administrative 21 14 — 172 207 Total $ 21 14 — 172 207 Capital expenditures $ 225 60 — — 285 Nine months ended April 30, 2021 Clinical Services Products Therapeutics Other Consolidated Revenues – Services and Products $ 70,229 $ 22,689 — — $ 92,918 Operating costs and expenses Cost of revenues 37,436 11,718 — — 49,154 Research and development 454 1,868 $ 66 — 2,388 Selling, general and administrative 19,552 7,848 50 $ 5,659 33,109 Legal and related expenses 191 16 — 3,786 3,993 Total operating costs and expenses 57,633 21,450 116 9,445 88,644 Operating income (loss) 12,596 1,239 (116 ) (9,445 ) 4,274 Other income (expense) Interest (14 ) 29 — (55 ) (40 ) Other 30 6 — (91 ) (55 ) Foreign exchange gain 428 — — 428 Net income (loss) $ 12,612 $ 1,702 $ (116 ) $ (9,591 ) $ 4,607 Depreciation and amortization included above $ 1,189 $ 581 $ — $ 198 $ 1,968 Share-based compensation included in above Selling, general and administrative 28 73 — 473 574 Cost of revenues 66 — — — 66 Total $ 94 $ 73 $ — $ 473 $ 640 Capital expenditures $ 2,425 $ 378 $ — $ 67 $ 2,870 Nine months ended April 30, 2020 Clinical Services Products Therapeutics Other Consolidated Revenues – Services and Products $ 35,032 $ 20,715 — — $ 55,747 Grant income 747 — — — 747 Total 35,779 20,715 56,494 Operating costs and expenses Cost of revenues 30,351 10,223 — — 40,574 Research and development 1,118 1,599 $ 565 — 3,282 Selling, general and administrative 18,012 7,954 — $ 6,927 32,893 Legal and related expenses 140 1 — 5,540 5,681 Total operating costs and expenses 49,621 19,777 565 12,467 82,430 Operating income (loss) (13,842 ) 938 (565 ) (12,467 ) (25,936 ) Other income (expense) Interest (29 ) 45 — 479 495 Other 20 (1 ) — 315 334 Foreign exchange loss — (88 ) — — (88 ) Net income (loss) $ (13,851 ) $ 894 $ (565 ) $ (11,673 ) $ (25,195 ) Depreciation and amortization included above $ 1,174 $ 781 $ — $ 196 $ 2,151 Share-based compensation included in above Selling, general and administrative. 88 58 — 582 728 Total $ 88 $ 58 $ — $ 582 $ 728 Capital expenditures $ 514 $ 205 $ — $ — $ 719

Contingencies

Contingencies	9 Months Ended
	Apr. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 12 Contingencies The Company has brought cases in the United States District Court for the District of Delaware (“the Court”), alleging patent infringement against various companies. In 2017, the Court ruled that the asserted claims of the ‘180 and ‘405 Patents are invalid for nonenablement in cases involving Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche. That ruling was affirmed by the United States Court of Appeals for the Federal Circuit (“Federal Circuit”) in June 2019. Enzo subsequently filed a petition for certiorari regarding the invalidity ruling for the ‘180 and ‘405 Patents in February 2020; the Supreme Court denied Enzo’s petition on March 30, 2020. There are currently two cases that were originally brought by the Company in the Court. In those two cases, Enzo alleges patent infringement against Becton Dickinson Defendants and Roche Defendants, respectively. The claims in those cases involve the ‘197 Patent. Both cases are stayed. In separate inter partes review proceedings before the U.S. Patent and Trademark Office involving, among others, Becton Dickinson, certain claims of the ‘197 Patent were found unpatentable as anticipated or obvious and cancelled by the Patent Trial and Appeals Board (“Board”). Enzo appealed that decision to the Federal Circuit. On August 16, 2019, the Federal Circuit affirmed the Board’s decision, finding that each of the challenged claims is unpatentable. The Company filed a petition for rehearing and rehearing en banc on October 30, 2019, which the Federal Circuit denied on December 4, 2019. The Company filed a petition for certiorari with the Supreme Court on March 3, 2020, which was denied. In April 2019, the Company entered into an agreement with Hologic and Grifols, resolving litigation resulting from four cases originally brought by the Company in the Court. As a result, Enzo dismissed (1) a stayed patent litigation regarding the ‘180 and ‘197 Patent against Hologic in the Court; (2) the Consolidated Appeals against Gen-Probe and Hologic resulting from two cases filed in the Court, and (3) the Company’s appeal in the litigation involving the ‘581 Patent that involved both Hologic and Grifols. As a result of the agreement with Hologic, Hologic withdrew from Enzo’s Federal Circuit appeal of the Board’s adverse rulings in the inter partes On February 5, 2020, Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (“Plaintiffs”) brought an action in the United States District Court for the Southern District of New York against the Company and five of its present or former Directors, Dr. Elazar Rabbani, Barry W. Weiner, Dr. Bruce A. Hanna, Dov Perlysky and Rebecca Fischer. On March 26, 2020, Plaintiffs filed an amended complaint against the same defendants. Count I asserted the Company violated Section 14(a) of the Securities and Exchange Act of 1934 and Rule 14a-9 thereunder by disseminating proxy materials that made two purportedly false statements: (a) a “January 28, 2020 Enzo press release [that purportedly] falsely stated that the Annual Meeting would be ‘delayed’ by action of the Board to February 25, 2020 when, in fact, the Annual Meeting would convene as planned on January 31, 2020”, and (b) a “January 31 Enzo Proxy [that purportedly] falsely stated that the Proposed By-Law Amendment [to Article II, Section 9] would be approved if it received…a majority of the votes….rather than the required Supermajority Vote as provided for in the Charter. “Count II asserted a claim against the individual defendants under Section 20(a) of the Exchange Act premised on Enzo’s purported violation of Section 14(a) and Rule 14a-9. Count III asserted the individual defendants breached their fiduciary duty, based on the same conduct and by seeking to entrench themselves. Finally, Count IV purported to assert a derivative claim for a declaration that any amendment to Article II, Section 2 requires the approval of 80% of Enzo’s shareholders. On July 16, 2020, the day before the defendants’ motion to dismiss was due, plaintiffs asked the Court to dismiss their claims without prejudice. Defendants asked plaintiffs to dismiss the claims with prejudice, but they refused. On July 17, 2020, the Court dismissed the claims without prejudice. If plaintiffs reassert the claims, defendants intend to vigorously defend against them. On November 27, 2020, the Company brought an action in the United States District Court for the Southern District of New York against Harbert Discovery Fund, LP, Harbert Discovery Co-Investment Fund I, LP, Harbert Fund Advisors, Inc., Harbert Management Corp. and Kenan Lucas. The Company alleges the defendants made false and misleading representations, or omitted to state material facts necessary to make their statements not misleading, in proxy materials they disseminated seeking the election to the Company’s Board of Directors at its 2019 Annual Meeting of two candidates they nominated, in violation of Section 14(a) of the 1934 Exchange Act and Rule 14a-9 thereunder. The Company seeks damages and injunctive relief. On February 15, 2021, Defendants filed a motion to dismiss. On March 8, 2021, the Company filed its opposition to that motion. On March 18, 2021 defendants filed their reply in further support of the motion. The motion is sub judice There can be no assurance that the Company will be successful in any of these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations. As described in Note 3, third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. During the third fiscal quarter of 2019, a significant third-party payer informed us outside of their typical business practice that they believe it overpaid the Company during certain periods of fiscal 2018. The Company disputed these claims and formally sent legal appeal letters to the payer. During the fiscal 2020 period, we recorded $0.8 million in legal and related expenses as a result of reduced reimbursements this payer made to us. In April 2020, we and the payer entered into a settlement agreement and release whereby the parties agreed that the $0.8 million previously withheld by the payer shall fully and completely satisfy the dispute.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
COVID 19 [Policy Text Block]	COVID 19 The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions including, but not limited to, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of April 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s patient self-pay revenue concessions and credit losses in the Clinical Services segment, accounts receivable, inventories and the carrying value of goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods. We fully expect COVID-19 volume to decline in the quarters ahead as the percentage of Americans who are vaccinated increases.
Effect of New Accounting Pronouncements	Effect of New Accounting Pronouncements Pronouncements Issued but Not Yet Adopted In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326) In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.
Concentration Risk	Concentration Risk Other than the Medicare program, two providers whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represent approximately 36% and 35% of Clinical Services net revenue for the three and nine month periods ended April 30, 2021. Other than the Medicare program, one provider whose programs are included in those categories represents approximately 21% of Clinical Services net revenue for both the three and nine month periods ended April 30, 2020. As of April 30, 2021, the Medicare program represents 15%, a provider in the third party category represents 13%, and a government payer in the patient self-pay category represents 10% of Clinical Services net receivables.
Income Taxes	Income Taxes The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. It is the Company’s policy to provide for uncertain tax positions, if any, and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. Due to our tax net operating loss carryforwards, we do not provide for an income tax provision on pre-tax income in the fiscal 2021 periods. We maintain a full valuation allowance on all tax assets and, as a consequence, do not provide any tax benefit for the fiscal 2020 period losses.
Fair Value Measurements	Fair Value Measurements The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest. Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level 3 Valuations derived from valuation techniques in which one or more significant inputs are unobservable.
Marketable securities	Marketable securities The Company limits its credit risk associated with investments by investing in a mutual fund and an exchange traded fund (ETF) which hold highly rated corporate bonds, asset backed securities, municipal bonds, mortgage obligations and government obligations. These investments are classified as trading securities and are Level 1 fair value investments. As of April 30, 2021, the fair value of these investments was $29,932 and the cost basis was $30,023. We recognized unrealized losses of $91 for the three and nine months ended April 30, 2021.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Apr. 30, 2021
Revenue from Contract with Customer [Abstract]
Schedule of segment revenue and revenue percentage	Three months ended Three months ended Revenue category Third-party payer $ 16,135 64 % $ 5,082 52 % Medicare 2,952 12 1,870 19 Patient self-pay 2,468 10 1,655 17 HMO’s 3,463 14 1,132 12 Total $ 25,018 100 % $ 9,739 100 % Nine months ended Nine months ended Revenue category Third-party payer $ 44,138 63 % $ 17,878 51 % Medicare 10,265 15 8,048 23 Patient self-pay 6,524 9 4,621 13 HMO’s 9,302 13 4,485 13 Total $ 70,229 100 % $ 35,032 100 %
Schedule of product revenue by geographical	Three Months Ended Nine Months Ended 2021 2020 2021 2020 United States $ 3,941 $ 3,520 $ 11,410 $ 11,854 Europe 2,732 1,802 7,798 5,777 Asia Pacific 1,106 1,095 3,481 3,084 Products revenue $ 7,779 $ 6,417 $ 22,689 $ 20,715

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Apr. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories	April 30, July 31, Raw materials $ 1,287 $ 1,019 Work in process 2,489 2,587 Finished products 7,231 4,178 $ 11,007 $ 7,784

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	9 Months Ended
	Apr. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets	Gross Accumulated Amortization Net July 31, 2020 $ 27,686 $ (27,148 ) $ 538 Amortization expense — (244 ) (244 ) Foreign currency translation 88 (67 ) 21 April 30, 2021 $ 27,774 $ (27,459 ) $ 315
Schedule of Intangible Assets	April 30, 2021 July 31, 2020 Gross Accumulated Net Gross Accumulated Net Patents $ 11,027 $ (11,027 ) $ — $ 11,027 (11,014 ) $ 13 Customer relationships 12,058 (11,743 ) 315 12,003 (11,478 ) 525 Website and acquired content 1,025 (1,025 ) — 1,022 (1,022 ) — Licensed technology and other 494 (494 ) — 483 (483 ) — Trademarks 3,170 (3,170 ) — 3,151 (3,151 ) — Total $ 27,774 $ (27,459 ) $ 315 $ 27,686 (27,148 ) $ 538
Schedule of Useful Lives For Acquisitions	Useful life assigned Weighted average Customer relationships 8 -15 years 1 year

Long term debt (Tables)

Long term debt (Tables)	9 Months Ended
	Apr. 30, 2021
Debt Disclosure [Abstract]
Schedule of minimum future annual principal payments	July 31, Total 2021 $ 7,037 2022 152 2023 160 2024 167 2025 603 Thereafter 3,476 Total principal payments 11,595 Less: current portion, included in other current liabilities and other short term debt (7,150 ) Unamortized mortgage cost (55 ) Long term debt - net $ 4,390

Leases (Tables)

Leases (Tables)	9 Months Ended
	Apr. 30, 2021
Leases Disclosure [Abstract]
Schedule of components lease	Leases Balance Sheet Classification April 30, 2021 Assets Operating Right-of-use assets $ 17,411 Finance Property, plant and equipment, net (a) 267 Total lease assets $ 17,678 Liabilities Current: Operating Current portion of operating lease liabilities $ 3,442 Finance Finance leases short term 72 Non-current: Operating Operating lease liabilities, non-current 14,916 Finance Other liabilities and finance leases long term 136 Total lease liabilities $ 18,566 (a) Accumulated amortization of finance lease assets was approximately $1.1 million as of April 30, 2021.
Schedule of lease cost	Three months ended Nine months ended 2021 2020 2021 2020 Operating lease cost $ 1,271 $ 1,466 $ 4,265 $ 4,414 Finance lease cost: Amortization of leased assets 19 61 118 177 Interest on lease liabilities 3 7 12 29 Total lease cost $ 1,293 $ 1,534 $ 4,395 $ 4,620
Schedule of lease liability maturity	Maturity of lease liabilities, years ending July 31, Operating leases Finance leases Total 2021 $ 1,181 $ 22 $ 1,203 2022 4,017 88 4,105 2023 3,318 88 3,406 2024 3,173 31 3,204 2025 3,145 — 3,145 Thereafter 6,370 — 6,370 Total lease payments 21,204 229 21,433 Less: Interest (a) (2,846 ) (18 ) (2,864 ) Present value of lease liabilities $ 18,358 $ 211 $ 18,569 (a) Primarily calculated using the Company’s incremental borrowing rate.
Schedule of lease term and discount rate	Lease term and discount rate Weighted-average remaining lease term (years): Operating leases 5.8 years Finance leases 2.7 years Weighted-average discount rate: Operating leases 4.97 % Finance leases 8.25 %

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Apr. 30, 2021
Payables and Accruals [Abstract]
Schedule of accrued liabilities	April 30, July 31, Payroll, benefits, and commissions $ 4,273 $ 5,227 Professional fees 627 710 Legal 2,909 2,647 Deferred revenue – CARES Act Advance Payment 2,414 2,526 Other 2,305 1,723 $ 12,528 $ 12,833

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended
	Apr. 30, 2021
Stockholders' Equity Note [Abstract]
Schedule of amounts of share-based compensation expense	Three months ended Nine months ended 2021 2020 2021 2020 Stock options and performance stock units $ 297 $ 206 $ 638 $ 724 Restricted stock — 1 2 4 $ 297 $ 207 $ 640 $ 728
Schedule of share-based payment arrangement	Three months ended Nine months ended 2021 2020 2021 2020 Selling, general and administrative $ 258 $ 207 $ 574 $ 728 Cost of revenues 39 — 66 — $ 297 $ 207 $ 640 $ 728
Schedule of stock option activity	Options Weighted Weighted Aggregate Outstanding at July 31, 2020 2,636,496 $ 4.05 Awarded 543,104 $ 2.57 Exercised (34,667 ) 2.80 $ Expired or forfeited (619,371 ) $ 3.40 Outstanding at end of period 2,525,562 $ 3.76 2.6 years $ 957 Exercisable at end of period 1,581,326 $ 1.6 years $
Schedule of nonvested performance-based units activity	Grant Date Total Grant Forfeitures Outstanding Fair Market Value At Grant Date (000s) 10/15/2018 32,000 (6,000 ) 26,000 $ 107 10/15/2019 80,500 (14,500 ) 66,000 $ 222 10/19/2020 98,600 — 98,600 $ 207

Segment reporting (Tables)

Segment reporting (Tables)	9 Months Ended
	Apr. 30, 2021
Segment Reporting [Abstract]
Schedule of financial information represents the operating results of the reportable segments	Three months ended April 30, 2021 Clinical Services Products Therapeutics Other Consolidated Revenues – Services and Products $ 25,018 $ 7,779 — — $ 32,797 Operating costs and expenses Cost of revenues 12,733 4,018 — — 16,751 Research and development 173 643 $ 20 — 836 Selling, general and administrative 7,029 2,810 17 $ 2,226 12,082 Legal and related expenses 95 10 — 956 1,061 Total operating costs and expenses 20,030 7,481 37 3,182 30,730 Operating income (loss) 4,988 298 (37 ) (3,182 ) 2,067 Other income (expense) Interest (4 ) 11 — 53 60 Other 1 2 — (91 ) (88 ) Foreign exchange gain — (33 ) — — (33 ) Net income (loss) $ 4,985 $ 278 $ (37 ) $ (3,220 ) $ 2,006 Depreciation and amortization included above $ 399 $ 208 $ — $ 66 $ 673 Share-based compensation included in above Selling, general and administrative 9 41 — 208 258 Cost of revenues 39 — — — 39 Total $ 48 $ 41 $ — $ 208 $ 297 Capital expenditures $ 1,544 $ 180 $ — $ 23 $ 1,747 Three months ended April 30, 2020 Clinical Services Products Therapeutics Other Consolidated Revenues $ 9,739 $ 6,417 — — $ 16,156 Grant income 747 — — — 747 Total 10,486 6,417 — — 16,903 Operating costs and expenses Cost of revenues 9,133 3,345 — — 12,478 Research and development 395 580 188 — 1,163 Selling, general and administrative 5,902 2,667 — 2,492 11,061 Legal fee expense 52 — — 1,873 1,925 Total operating costs and expenses 15,482 6,592 188 4,365 26,627 Operating loss (4,996 ) (175 ) (188 ) (4,365 ) (9,724 ) Other income (expense) Interest (7 ) 11 — 83 87 Other 1 4 — 130 135 Foreign exchange loss — (358 ) — — (358 ) Net loss $ (5,002 ) (518 ) (188 ) (4,152 ) (9,860 ) Depreciation and amortization included above $ 373 278 — 66 717 Share-based compensation included in above Selling, general and administrative 21 14 — 172 207 Total $ 21 14 — 172 207 Capital expenditures $ 225 60 — — 285 Nine months ended April 30, 2021 Clinical Services Products Therapeutics Other Consolidated Revenues – Services and Products $ 70,229 $ 22,689 — — $ 92,918 Operating costs and expenses Cost of revenues 37,436 11,718 — — 49,154 Research and development 454 1,868 $ 66 — 2,388 Selling, general and administrative 19,552 7,848 50 $ 5,659 33,109 Legal and related expenses 191 16 — 3,786 3,993 Total operating costs and expenses 57,633 21,450 116 9,445 88,644 Operating income (loss) 12,596 1,239 (116 ) (9,445 ) 4,274 Other income (expense) Interest (14 ) 29 — (55 ) (40 ) Other 30 6 — (91 ) (55 ) Foreign exchange gain 428 — — 428 Net income (loss) $ 12,612 $ 1,702 $ (116 ) $ (9,591 ) $ 4,607 Depreciation and amortization included above $ 1,189 $ 581 $ — $ 198 $ 1,968 Share-based compensation included in above Selling, general and administrative 28 73 — 473 574 Cost of revenues 66 — — — 66 Total $ 94 $ 73 $ — $ 473 $ 640 Capital expenditures $ 2,425 $ 378 $ — $ 67 $ 2,870 Nine months ended April 30, 2020 Clinical Services Products Therapeutics Other Consolidated Revenues – Services and Products $ 35,032 $ 20,715 — — $ 55,747 Grant income 747 — — — 747 Total 35,779 20,715 56,494 Operating costs and expenses Cost of revenues 30,351 10,223 — — 40,574 Research and development 1,118 1,599 $ 565 — 3,282 Selling, general and administrative 18,012 7,954 — $ 6,927 32,893 Legal and related expenses 140 1 — 5,540 5,681 Total operating costs and expenses 49,621 19,777 565 12,467 82,430 Operating income (loss) (13,842 ) 938 (565 ) (12,467 ) (25,936 ) Other income (expense) Interest (29 ) 45 — 479 495 Other 20 (1 ) — 315 334 Foreign exchange loss — (88 ) — — (88 ) Net income (loss) $ (13,851 ) $ 894 $ (565 ) $ (11,673 ) $ (25,195 ) Depreciation and amortization included above $ 1,174 $ 781 $ — $ 196 $ 2,151 Share-based compensation included in above Selling, general and administrative. 88 58 — 582 728 Total $ 88 $ 58 $ — $ 582 $ 728 Capital expenditures $ 514 $ 205 $ — $ — $ 719

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Basis of Presentation (Details) [Line Items]
Fair value investments (in Dollars)	$ 29,932		$ 29,932
Cost of marketable securities (in Dollars)	30,023		30,023
Unrealized losses marketable securities (in Dollars)	$ 91		$ 91
Medicare Program [Member]
Basis of Presentation (Details) [Line Items]
Concentration risk, percentage			15.00%
Third Party Category [Member]
Basis of Presentation (Details) [Line Items]
Concentration risk, percentage			13.00%
Clinical Services [Member]
Basis of Presentation (Details) [Line Items]
Concentration risk, percentage			10.00%
Clinical Services [Member] | Third-party payers” and “Health Maintenance Organizations [Member] | Revenue Benchmark [Member]
Basis of Presentation (Details) [Line Items]
Concentration risk, percentage	36.00%	21.00%	35.00%	21.00%

Net income (loss) per share (De

Net income (loss) per share (Details) - shares	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Net income (loss) per share (Details) [Line Items]
Weighted average stock options of diluted weighted average shares outstanding	397,000		104,000
Unvested Restricted Stock [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		40,000		56,000
Out of the money options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	814,000	2,201,000	1,686,000	1,805,000

Revenue Recognition (Details)

Revenue Recognition (Details)	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Revenue Recognition (Details) [Line Items]
Revenue, percentage		58.00%		58.00%
Government Payer - Medicare [Member]
Revenue Recognition (Details) [Line Items]
Billing information filing deadline period			60 days
Patient Selfpay [Member]
Revenue Recognition (Details) [Line Items]
Billing period			91 days
Receivable collection period			105 days
Products Revenue [Member]
Revenue Recognition (Details) [Line Items]
Claim period for return of goods			30 days
Minimum [Member] | Third party payers and health maintenance organizations [Member]
Revenue Recognition (Details) [Line Items]
Billing information filing deadline period			30 days
Minimum [Member] | Products Revenue [Member]
Revenue Recognition (Details) [Line Items]
Receivable collection period			30 days
Maximum [Member] | Third party payers and health maintenance organizations [Member]
Revenue Recognition (Details) [Line Items]
Billing information filing deadline period			90 days
Maximum [Member] | Products Revenue [Member]
Revenue Recognition (Details) [Line Items]
Receivable collection period			90 days
Clinical Services Revenue [Member]
Revenue Recognition (Details) [Line Items]
Concentration risk, percentage	76.00%		76.00%

Revenue Recognition (Details) -

Revenue Recognition (Details) - Schedule of segment revenue and revenue percentage - Clinical Services [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Revenue Recognition (Details) - Schedule of segment revenue and revenue percentage [Line Items]
Revenue services net	$ 25,018	$ 9,739	$ 70,229	$ 35,032
Revenue services net, percentage	100.00%	100.00%	100.00%	100.00%
Third party payers [Member]
Revenue Recognition (Details) - Schedule of segment revenue and revenue percentage [Line Items]
Revenue services net	$ 16,135	$ 5,082	$ 44,138	$ 17,878
Revenue services net, percentage	64.00%	52.00%	63.00%	51.00%
Medicare [Member]
Revenue Recognition (Details) - Schedule of segment revenue and revenue percentage [Line Items]
Revenue services net	$ 2,952	$ 1,870	$ 10,265	$ 8,048
Revenue services net, percentage	12.00%	19.00%	15.00%	23.00%
Patient Selfpay [Member]
Revenue Recognition (Details) - Schedule of segment revenue and revenue percentage [Line Items]
Revenue services net	$ 2,468	$ 1,655	$ 6,524	$ 4,621
Revenue services net, percentage	10.00%	17.00%	9.00%	13.00%
HMO’s [Member]
Revenue Recognition (Details) - Schedule of segment revenue and revenue percentage [Line Items]
Revenue services net	$ 3,463	$ 1,132	$ 9,302	$ 4,485
Revenue services net, percentage	14.00%	12.00%	13.00%	13.00%

Revenue Recognition (Details)_2

Revenue Recognition (Details) - Schedule of Product revenue by geographical - Product Revenue [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Revenue Recognition (Details) - Schedule of Product revenue by geographical [Line Items]
Products revenue	$ 7,779	$ 6,417	$ 22,689	$ 20,715
United States [Member]
Revenue Recognition (Details) - Schedule of Product revenue by geographical [Line Items]
Products revenue	3,941	3,520	11,410	11,854
Europe [Member]
Revenue Recognition (Details) - Schedule of Product revenue by geographical [Line Items]
Products revenue	2,732	1,802	7,798	5,777
Asia Pacific [Member]
Revenue Recognition (Details) - Schedule of Product revenue by geographical [Line Items]
Products revenue	$ 1,106	$ 1,095	$ 3,481	$ 3,084

Supplemental Disclosure for S_2

Supplemental Disclosure for Statement of Cash Flows (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Jan. 31, 2021	Apr. 30, 2021	Apr. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Interest paid		$ 177	$ 204
Reductions in measurement right of use assets and liabilities		$ 67	$ 127
Common stock to executives (in Shares)	332,700
Accrued bonuses	$ 875
Issued shares of common stock (in Shares)		208,537	333,265
Share based compensation		$ 780	$ 836

Inventories (Details) - Schedul

Inventories (Details) - Schedule of Inventories - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
Schedule of Inventories [Abstract]
Raw materials	$ 1,287	$ 1,019
Work in process	2,489	2,587
Finished products	7,231	4,178
Total inventories	$ 11,007	$ 7,784

Goodwill and intangible asset_2

Goodwill and intangible assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2021	Jul. 31, 2020	Apr. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 7,452	$ 7,452	$ 7,452
Weighted average remaining useful life	1 year

Goodwill and intangible asset_3

Goodwill and intangible assets (Details) - Schedule of Indefinite-Lived Intangible Assets $ in Thousands	9 Months Ended
	Apr. 30, 2021USD ($)
Schedule of Indefinite-Lived Intangible Assets [Abstract]
Gross, Beginning Balance	$ 27,686
Accumulated Amortization, Beginning Balance	(27,148)
Net, Beginning Balance	538
Amortization expense, Gross
Amortization expense, Accumulated Amortization	(244)
Amortization expense, Net	(244)
Foreign currency translation, Gross	88
Foreign currency translation, Accumulated Amortization	(67)
Foreign currency translation, Net	21
Gross, Ending Balance	27,774
Accumulated Amortization, Ending Balance	(27,459)
Net, Ending Balance	$ 315

Goodwill and intangible asset_4

Goodwill and intangible assets (Details) - Schedule of Intangible Assets - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	$ 27,774	$ 27,686
Finite-lived intangible assets, Accumulated Amortization	(27,459)	(27,148)
Finite-lived intangible assets, Net	315	538
Patents [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	11,027	11,027
Finite-lived intangible assets, Accumulated Amortization	(11,027)	(11,014)
Finite-lived intangible assets, Net		13
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	12,058	12,003
Finite-lived intangible assets, Accumulated Amortization	(11,743)	(11,478)
Finite-lived intangible assets, Net	315	525
Website and Acquired Content [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	1,025	1,022
Finite-lived intangible assets, Accumulated Amortization	(1,025)	(1,022)
Finite-lived intangible assets, Net
Licensed Technology and Other [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	494	483
Finite-lived intangible assets, Accumulated Amortization	(494)	(483)
Finite-lived intangible assets, Net
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	3,170	3,151
Finite-lived intangible assets, Accumulated Amortization	(3,170)	(3,151)
Finite-lived intangible assets, Net

Goodwill and intangible asset_5

Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions - Customer Relationships [Member]	9 Months Ended
	Apr. 30, 2021
Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions [Line Items]
Weighted average remaining useful life	1 year
Minimum [Member]
Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions [Line Items]
Useful life assigned	8 years
Maximum [Member]
Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions [Line Items]
Useful life assigned	15 years

Long term debt (Details)

Long term debt (Details) $ in Thousands, SFr in Millions	1 Months Ended	9 Months Ended
	Nov. 30, 2018USD ($)	Apr. 30, 2021USD ($)	Apr. 30, 2020USD ($)	Apr. 30, 2020CHF (SFr)
Long term debt (Details) [Line Items]
Debt instrument, face amount	$ 4,500
Debt instrument maturity period	10 years
Debt instrument, interest rate, stated percentage	5.09%
Debt instrument, periodic payment	$ 30
Amortization of debt issuance costs	$ 72
Unamortized debt issuance expense		$ 55
Mortgage agreement		4,200
Cash collateral for borrowed securities		$ 750
Operating lease, description		We assumed from the seller an operating lease for a tenant at the facility which expired on June 30, 2020.
Liquid assets		$ 25,000
Foreign exchange rate amount		$ 400		SFr 0.4
Bear interest rate		0.00%
Long term debt term		5 years
Fixed interest rate, description		PPP loans have a 1% fixed interest rate and are due from two to five years.
Maturity date, description		The PPP Loan matures on April 17, 2022 (the “Maturity Date”), accrues interest at 1% per annum and may be prepaid in whole or in part without penalty.
Intention to audit loans in excess		$ 2,000
Excess loans		$ 2,000
Citibank N.A [Member]
Long term debt (Details) [Line Items]
Cash collateral for borrowed securities			$ 7,000

Long term debt (Details) - Sche

Long term debt (Details) - Schedule of minimum future annual principal payments - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
Schedule of minimum future annual principal payments [Abstract]
2021	$ 7,037
2022	152
2023	160
2024	167
2025	603
Thereafter	3,476
Total principal payments	11,595
Less: current portion, included in other current liabilities and other short term debt	(7,150)
Unamortized mortgage cost	(55)
Long term debt - net	$ 4,390	$ 4,485

Leases (Details)

Leases (Details) $ in Millions	9 Months Ended
	Apr. 30, 2021USD ($)
Leases (Details) [Line Items]
Lease option maximum extension period	5 years
Accumulated amortization of finance lease assets (in Dollars)	$ 1.1
Minimum [Member]
Leases (Details) [Line Items]
Lease term of contract	1 year
Maximum [Member]
Leases (Details) [Line Items]
Lease term of contract	8 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of components lease - USD ($) $ in Thousands		Apr. 30, 2021	Jul. 31, 2020
Assets
Operating, Right-of-use assets		$ 17,411	$ 19,916
Finance, Property, plant and equipment, net	[1]	267
Total lease assets		17,678
Current:
Operating, Current portion of operating lease liabilities		3,442	4,121
Finance, Finance leases short term		72
Non-current:
Operating, Operating lease liabilities, non-current		14,916	$ 16,679
Finance, Other liabilities and finance leases long term		136
Total lease liabilities		$ 18,566
[1]	Accumulated amortization of finance lease assets was approximately $1.1 million as of April 30, 2021.

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of lease cost - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Schedule of lease cost [Abstract]
Operating lease cost	$ 1,271	$ 1,466	$ 4,265	$ 4,414
Finance lease cost:
Amortization of leased assets	19	61	118	177
Interest on lease liabilities	3	7	12	29
Total lease cost	$ 1,293	$ 1,534	$ 4,395	$ 4,620

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of lease liability maturity $ in Thousands	Jul. 31, 2020USD ($)
Schedule of lease liability maturity [Abstract]
2021, Operating leases	$ 1,181
2021, Finance leases	22
2021, Total	1,203
2022, Operating leases	4,017
2022, Finance leases	88
2022, Total	4,105
2023, Operating leases	3,318
2023, Finance leases	88
2023, Total	3,406
2024, Operating leases4	3,173
2024, Finance leases	31
2024, Total	3,204
2025, Operating leases4	3,145
2025, Finance leases
2025, Total	3,145
Thereafter, Operating leases	6,370
Thereafter, Finance lease
Thereafter, Total	6,370
Total lease payments, Operating leases	21,204
Total lease payments, Finance leases	229
Total lease payments, Total	21,433
Less: Interest, Operating leases	(2,846)	[1]
Less: Interest, Finance leases	(18)	[1]
Less: Interest, Total	(2,864)	[1]
Present value of lease liabilities, Operating leases	18,358
Present value of lease liabilities, Finance leases	211
Present value of lease liabilities, Total	$ 18,569
[1]	Primarily calculated using the Company’s incremental borrowing rate.

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of lease term and discount rate	Apr. 30, 2021
Weighted-average remaining lease term (years):
Weighted-average remaining lease term: Operating leases	5 years 292 days
Weighted-average remaining lease term: Finance leases	2 years 255 days
Weighted-average discount rate:
Weighted-average discount rate: Operating leases	4.97%
Weighted-average discount rate: Finance leases	8.25%

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2021
Payables and Accruals [Abstract]
Payment advance	$ 2,526
Accrual, real and personal property taxes, uncertainty		25%
Accrued liabilities and other liabilities		$ 243

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($) $ in Thousands	Apr. 30, 2021	Jul. 31, 2020
Schedule of accrued liabilities [Abstract]
Payroll, benefits, and commissions	$ 4,273	$ 5,227
Professional fees	627	710
Legal	2,909	2,647
Deferred revenue – CARES Act Advance Payment	2,414	2,526
Other	2,305	1,723
Accrued liabilities	$ 12,528	$ 12,833

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		9 Months Ended
	Jan. 05, 2018	Sep. 30, 2017	Apr. 30, 2021	Apr. 30, 2020	Jul. 31, 2020	Dec. 31, 2014	Jan. 31, 2011
Stockholders’ Equity (Details) [Line Items]
Common stock, par value (in Dollars per share)			$ 0.01		$ 0.01
Percentage of commission payable on equity offering			3.00%
Maximum offering price under sales agreement			$ 20,000			$ 20,000
Common stock available for grant, description			The amendment and restatement of the Amended and Restated 2011 Plan was for purposes of, among other things, (i) increasing the shares of common stock available for grant under the Amended and Restated 2011 Plan by an additional 4,000,000 shares of common stock bringing the total number of shares available for grant to 9,000,000 shares of common stock and (ii) extending the term of the Amended and Restated 2011 Plan until October 7, 2030.
Share-based compensation arrangement by share-based payment award, number of shares available for grant (in Shares)			4,834,000
Compensation cost related to non-vested options			$ 916
Performance share, description			During the nine months ended April 30, 2021, one former executive forfeited a total of 6,000 PSUs. During the nine months ended April 30, 2020, one former executive forfeited a total of 14,500 PSUs.
Compensation expense			$ 162	$ 0
2011 Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Share based compensation arrangement by share based payment award restricted stock units (in Shares)							3,000,000
Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in Shares)	2,000,000
Common stock available for grants (in Shares)	5,000,000
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Authorized common stock that may be issued and sold under sales agreement		$ 19,200
Securities that may be sold under the agreement		$ 150,000

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - Schedule of amounts of share-based compensation expense - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Stockholders’ Equity (Details) - Schedule of amounts of share-based compensation expense [Line Items]
Share-based compensation expense	$ 297	$ 207	$ 640	$ 728
Stock options and performance stock units [Member]
Stockholders’ Equity (Details) - Schedule of amounts of share-based compensation expense [Line Items]
Share-based compensation expense	$ 297	206	638	724
Restricted stock [Member]
Stockholders’ Equity (Details) - Schedule of amounts of share-based compensation expense [Line Items]
Share-based compensation expense		$ 1	$ 2	$ 4

Stockholders_ Equity (Details_2

Stockholders’ Equity (Details) - Schedule of share-based payment arrangement - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payment arrangement	$ 297	$ 207	$ 640	$ 728
Selling, general and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payment arrangement	258	207	574	728
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payment arrangement	$ 39		$ 66

Stockholders_ Equity (Details_3

Stockholders’ Equity (Details) - Schedule of stock option activity $ / shares in Units, $ in Thousands	9 Months Ended
	Apr. 30, 2021USD ($)$ / sharesshares
Schedule of stock option activity [Abstract]
Outstanding beginning, Options	2,636,496
Outstanding beginning, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 4.05
Awarded, Options	543,104
Awarded, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 2.57
Exercised, Options	(34,667)
Exercised, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 2.80
Cancelled or expired, Options	(619,371)
Cancelled or expired, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 3.40
Outstanding at end of period, Options	2,525,562
Outstanding at end of period, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 3.76
Outstanding at end of period, Weighted Average Remaining Contractual Term	2 years 219 days
Outstanding at end of period, Aggregate Intrinsic Value (in Dollars) | $	$ 957
Exercisable at end of period, Options	1,581,326
Exercisable at end of period, Weighted Average Remaining Contractual Term	1 year 219 days

Stockholders_ Equity (Details_4

Stockholders’ Equity (Details) - Schedule of nonvested performance-based units activity - Executive Officer [Member] - USD ($) $ in Thousands	Oct. 15, 2019	Oct. 15, 2018	Oct. 19, 2020
Performance share 1 [Member]
Stockholders’ Equity (Details) - Schedule of nonvested performance-based units activity [Line Items]
Total Grant		32,000
Forfeitures		(6,000)
Outstanding		26,000
Fair Market Value At Grant Date (in Dollars)		$ 107
Performance share 2 [Member]
Stockholders’ Equity (Details) - Schedule of nonvested performance-based units activity [Line Items]
Total Grant	80,500
Forfeitures	(14,500)
Outstanding	66,000
Fair Market Value At Grant Date (in Dollars)	$ 222
Performance share 3 [Member]
Stockholders’ Equity (Details) - Schedule of nonvested performance-based units activity [Line Items]
Total Grant			98,600
Forfeitures
Outstanding			98,600
Fair Market Value At Grant Date (in Dollars)			$ 207

Segment reporting (Details)

Segment reporting (Details)	9 Months Ended
	Apr. 30, 2021
Segment Reporting [Abstract]
Number of reportable segments	3

Segment reporting (Details) - S

Segment reporting (Details) - Schedule of financial information represents the operating results of the reportable segments - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Clinical Services [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products	$ 25,018	$ 9,739	$ 70,229	$ 35,032
Grant income		747		747
Cost of revenues	12,733	9,133	37,436	30,351
Total		10,486		35,779
Capital expenditures	1,544	225	2,425	514
Research and development	173	395	454	1,118
Selling, general and administrative	7,029	5,902	19,552	18,012
Legal and related expenses	95	52	191	140
Total operating costs and expenses	20,030	15,482	57,633	49,621
Operating income (loss)	4,988	(4,996)	12,596	(13,842)
Interest	(4)	(7)	(14)	(29)
Other	1	1	30	20
Foreign exchange loss
Net income (loss)	4,985	(5,002)	12,612	(13,851)
Depreciation and amortization included above	399	373	1,189	1,174
Products [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products	7,779	6,417	22,689	20,715
Cost of revenues	4,018	3,345	11,718	10,223
Total		6,417		20,715
Capital expenditures	180	60	378	205
Research and development	643	580	1,868	1,599
Selling, general and administrative	2,810	2,667	7,848	7,954
Legal and related expenses	10		16	1
Total operating costs and expenses	7,481	6,592	21,450	19,777
Operating income (loss)	298	(175)	1,239	938
Interest	11	11	29	45
Other	2	4	6	(1)
Foreign exchange loss	(33)	(358)	428	(88)
Net income (loss)	278	(518)	1,702	894
Depreciation and amortization included above	208	278	581	781
Therapeutics [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products
Cost of revenues
Capital expenditures
Research and development	20	188	66	565
Selling, general and administrative	17		50
Legal and related expenses
Total operating costs and expenses	37	188	116	565
Operating income (loss)	(37)	(188)	(116)	(565)
Interest
Other
Foreign exchange loss
Net income (loss)	(37)	(188)	(116)	(565)
Depreciation and amortization included above
Other [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products
Cost of revenues
Capital expenditures	23		67
Research and development
Selling, general and administrative	2,226	2,492	5,659	6,927
Legal and related expenses	956	1,873	3,786	5,540
Total operating costs and expenses	3,182	4,365	9,445	12,467
Operating income (loss)	(3,182)	(4,365)	(9,445)	(12,467)
Interest	53	83	(55)	479
Other	(91)	130	(91)	315
Foreign exchange loss
Net income (loss)	(3,220)	(4,152)	(9,591)	(11,673)
Depreciation and amortization included above	66	66	198	196
Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products	32,797	16,156	92,918	55,747
Grant income		747		747
Cost of revenues	16,751	12,478	49,154	40,574
Total		16,903		56,494
Capital expenditures	1,747	285	2,870	719
Research and development	836	1,163	2,388	3,282
Selling, general and administrative	12,082	11,061	33,109	32,893
Legal and related expenses	1,061	1,925	3,993	5,681
Total operating costs and expenses	30,730	26,627	88,644	82,430
Operating income (loss)	2,067	(9,724)	4,274	(25,936)
Interest	60	87	(40)	495
Other	(88)	135	(55)	334
Foreign exchange loss	(33)	(358)	428	(88)
Net income (loss)	2,006	(9,860)	4,607	(25,195)
Depreciation and amortization included above	673	717	1,968	2,151
Selling, General and Administrative Expenses [Member] | Clinical Services [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	9	21	28	88
Selling, General and Administrative Expenses [Member] | Products [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	41	14	73	58
Selling, General and Administrative Expenses [Member] | Therapeutics [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative
Selling, General and Administrative Expenses [Member] | Other [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	208	172	473	582
Selling, General and Administrative Expenses [Member] | Consolidated [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	258	207	574	728
Cost of Revenues [Member] | Clinical Services [Member]
Segment Reporting Information [Line Items]
Cost of revenues	39		66
Cost of Revenues [Member] | Products [Member]
Segment Reporting Information [Line Items]
Cost of revenues
Cost of Revenues [Member] | Therapeutics [Member]
Segment Reporting Information [Line Items]
Cost of revenues
Cost of Revenues [Member] | Other [Member]
Segment Reporting Information [Line Items]
Cost of revenues
Cost of Revenues [Member] | Consolidated [Member]
Segment Reporting Information [Line Items]
Cost of revenues	39		66
Total [Member] | Clinical Services [Member]
Segment Reporting Information [Line Items]
Total	48	21	94	88
Total [Member] | Products [Member]
Segment Reporting Information [Line Items]
Total	41	14	73	58
Total [Member] | Therapeutics [Member]
Segment Reporting Information [Line Items]
Total
Total [Member] | Other [Member]
Segment Reporting Information [Line Items]
Total	208	172	473	582
Total [Member] | Consolidated [Member]
Segment Reporting Information [Line Items]
Total	$ 297	$ 207	$ 640	$ 728

Contingencies (Details)

Contingencies (Details) - USD ($) $ in Millions	1 Months Ended	9 Months Ended	12 Months Ended
	Apr. 30, 2020	Apr. 30, 2021	Jul. 31, 2020
Loss Contingency [Abstract]
Contingencies approval, percent		80.00%
Legal and related expenses			$ 0.8
Litigation settlement, amount awarded from other party	$ 0.8